https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Patient Access to Medical Insurance Covered Orphan Drugs in China: Real-World Evidence From Patient Survey https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50657 Wed 28 Feb 2024 16:28:37 AEDT ]]> Treatment of irritable bowel syndrome in China: a review https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22866 Wed 11 Apr 2018 13:29:38 AEST ]]> Budget impact analysis of increasing prescription of renin-angiotensin system inhibitors drugs to standard anti-hypertensive treatments in patients with diabetes and hypertension in a hypothetical cohort of Malaysian population https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36659 Wed 10 Nov 2021 15:14:22 AEDT ]]> Can the direct medical cost of chronic disease be transferred across different countries? Using cost-of-illness studies on type 2 diabetes, epilepsy and schizophrenia as examples https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24618 Wed 10 Nov 2021 15:13:29 AEDT ]]> Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43137 Tue 13 Sep 2022 15:14:32 AEST ]]> Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25354 Sat 24 Mar 2018 07:24:42 AEDT ]]>